Improvement in eGFR Slope with Iptacopan in C3 Glomerulonephritis with Complement Factor B Variant (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0743; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Despite treatment with angiotensin-converting enzyme inhibitors, corticosteroids, and mycophenolate mofetil, nephrotic-range proteinuria persisted. The concurrent improvement in complement activity and eGFR supports a treatment-related effect rather than spontaneous fluctuation. Given the mechanistic alignment between factor B inhibition and the underlying abnormality, this case supports a precision medicine approach."
Complement-mediated Rare Disorders • Glomerulonephritis • Lupus Nephritis • Nephrology • Renal Disease • CFB
|
|
Hideki Matsumura; Yuko Fujii; Tomoko Tanaka; Satoshi Yamazaki; Akihiko Shirasu; Hyogo Nakakura; Akira Ashida
|